You might want to take a look at G1 Therapeutics Inc. (GTHX) now

G1 Therapeutics Inc. (NASDAQ: GTHX) stock jumped 24.02% on Friday to $13.01 against a previous-day closing price of $10.49. With 2.38 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.27 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $13.03 whereas the lowest price it dropped to was $9.82. The 52-week range on GTHX shows that it touched its highest point at $16.76 and its lowest point at $3.84 during that stretch. It currently has a 1-year price target of $38.17. Beta for the stock currently stands at 2.21.

Do You Know The Best Place To Find Gains In Volatile Markets?

In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.

Click here for full details and to join for free.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GTHX was up-trending over the past week, with a rise of 56.18%, but this was up by 111.89% over a month. Three-month performance surged to 148.28% while six-month performance rose 37.53%. The stock lost -19.49% in the past year, while it has gained 27.42% so far this year. A look at the trailing 12-month EPS for GTHX yields -4.03 with Next year EPS estimates of -2.86. For the next quarter, that number is -0.64. This implies an EPS growth rate of -35.00% for this year and 25.20% for next year.

Float and Shares Shorts:

At present, 42.71 million GTHX shares are outstanding with a float of 38.82 million shares on hand for trading. On Jul 14, 2022, short shares totaled 4.77 million, which was 11.18% higher than short shares on Jun 14, 2022. In addition to Mr. John E. Bailey Jr. as the firm’s CEO, Pres & Director, Ms. Jennifer K. Moses CPA serves as its Chief Financial Officer.

Institutional Ownership:

Through their ownership of 59.77% of GTHX’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 31.26% of GTHX, in contrast to 26.40% held by mutual funds. Shares owned by individuals account for 20.51%. As the largest shareholder in GTHX with 6.42% of the stake, BlackRock Fund Advisors holds 2,741,028 shares worth 2,741,028. A second-largest stockholder of GTHX, Fisher Asset Management LLC, holds 2,311,138 shares, controlling over 5.41% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in GTHX, holding 1,850,785 shares or 4.33% stake. With a 2.95% stake in GTHX, the JPMorgan Small Cap Growth Fund is the largest stakeholder. A total of 1,259,226 shares are owned by the mutual fund manager. The Vanguard Total Stock Market Index, which owns about 2.48% of GTHX stock, is the second-largest Mutual Fund holder. It holds 1,058,647 shares valued at 5.23 million. LO Selection – NextGen BioTech holds 2.25% of the stake in GTHX, owning 961,139 shares worth 4.75 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for GTHX since 8 analysts follow the stock currently. There are 6 analysts who recommend BUY ratings, while 1 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With GTHX analysts setting a high price target of $67.00 and a low target of $17.00, the average target price over the next 12 months is $35.14. Based on these targets, GTHX could surge 414.99% to reach the target high and rise by 30.67% to reach the target low. Reaching the average price target will result in a growth of 170.1% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. GTHX will report FY 2022 earnings on 02/22/2023. Analysts have provided yearly estimates in a range of -$3.01 being high and -$4.19 being low. For GTHX, this leads to a yearly average estimate of -$3.54. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. G1 Therapeutics Inc. surprised analysts by $0.10 when it reported -$0.92 EPS against a consensus estimate of -$1.02. The surprise factor in the prior quarter was -$0.17. Based on analyst estimates, the high estimate for the next quarter is -$0.44 and the low estimate is -$1.01. The average estimate for the next quarter is thus -$0.68.

Summary of Insider Activity:

Insiders traded GTHX stock several times over the past three months with 5 Buys and 2 Sells. In these transactions, 50,000 shares were bought while 1,296 shares were sold. The number of buy transactions has increased to 17 while that of sell transactions has risen to 8 over the past year. The total number of shares bought during that period was 229,333 while 42,646 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *